{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:04:48Z","timestamp":1793192688167,"version":"4.5.0"},"reference-count":244,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD007804"],"award-info":[{"award-number":["U01FD007804"]}],"id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Description<\/jats:title>\n                    <jats:p>The American Society of Addiction Medicine (ASAM) has partnered with nine other medical societies and professional associations representing a wide range of clinical settings and patient populations to provide guidance on evidence-based strategies for tapering benzodiazepine (BZD) medication across a variety of settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The guideline was developed following modified GRADE methodology and clinical consensus process. The process included a systematic literature review as well as several targeted supplemental searches. The clinical practice guideline was revised based on external stakeholder review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recommendations<\/jats:title>\n                    <jats:p>Key takeaways included the following: Clinicians should engage in ongoing risk\u2013benefit assessment of BZD use\/tapering, clinicians should utilize shared decision-making strategies in collaboration with patients, clinicians should not discontinue BZDs abruptly in patients who are likely to be physically dependent and at risk of withdrawal, clinicians should tailor tapering strategies to each patient and adjust tapering based on patient response, and clinicians should offer patients adjunctive psychosocial interventions to support successful tapering.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-09499-2","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T01:58:11Z","timestamp":1750125491000},"page":"2814-2859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits"],"prefix":"10.1007","volume":"40","author":[{"given":"Emily","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chwen-Yuen A.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donovan","family":"Maust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"Mazer-Amirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Mecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Najera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyere","family":"Ogbonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran F.","family":"Rajneesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Snodgrass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"VandenBerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Devoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Framnes-DeBoer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethea","family":"Kleykamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Norrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Clinical Guideline Committee (CGC) Members","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chwen-Yuen A.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donovan","family":"Maust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"Mazer-Amirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Mecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Najera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyere","family":"Ogbonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran F.","family":"Rajneesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Snodgrass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"VandenBerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ASAM Staff and Contractors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Devoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Framnes-DeBoer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethea","family":"Kleykamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Norrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"9499_CR1","unstructured":"Centers for Disease Control and Prevention. Multiple Cause of Death Data 2000-2020 on CDC WONDER Online Database. December 2021 ed. CDC WONDER: Centers for Disease Control and Prevention, National Center for Health Statistics; 2021."},{"issue":"12","key":"9499_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147-1157. https:\/\/doi.org\/10.1056\/NEJMra1611832","journal-title":"N Engl J Med."},{"issue":"12","key":"9499_CR3","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","volume":"106","author":"M Lader","year":"2011","unstructured":"Lader M. Benzodiazepines revisited--will we ever learn? Addiction. 2011;106(12):2086-2109. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03563.x","journal-title":"Addiction."},{"key":"9499_CR4","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication. Updated 09-23-2020. Accessed August 1, 2024. https:\/\/www.fda.gov\/media\/142368\/download"},{"key":"9499_CR5","unstructured":"U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health 2023 Detail Files. Retrieved from https:\/\/datafiles.samhsa.gov. 2024."},{"key":"9499_CR6","unstructured":"Symphony Health Metys\u2122, data years 2013-2023. June 2024."},{"issue":"4","key":"9499_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","volume":"106","author":"MA Bachhuber","year":"2016","unstructured":"Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 2016;106(4):686-688. https:\/\/doi.org\/10.2105\/AJPH.2016.303061","journal-title":"Am J Public Health."},{"issue":"4","key":"9499_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","volume":"49","author":"CM Jones","year":"2015","unstructured":"Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015;49(4):493-501. https:\/\/doi.org\/10.1016\/j.amepre.2015.03.040","journal-title":"Am J Prev Med."},{"issue":"2","key":"9499_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136-142. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1763","journal-title":"JAMA Psychiatry."},{"issue":"11","key":"9499_CR10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1001\/jamainternmed.2018.2413","volume":"178","author":"LB Gerlach","year":"2018","unstructured":"Gerlach LB, Maust DT, Leong SH, Mavandadi S, Oslin DW. Factors associated with long-term benzodiazepine use among older adults. JAMA Intern Med. 2018;178(11):1560-1562. https:\/\/doi.org\/10.1001\/jamainternmed.2018.2413","journal-title":"JAMA Intern Med."},{"issue":"2","key":"9499_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.comppsych.2003.12.007","volume":"45","author":"CC Kan","year":"2004","unstructured":"Kan CC, Hilberink SR, Breteler MH. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry. 2004;45(2):88-94. https:\/\/doi.org\/10.1016\/j.comppsych.2003.12.007","journal-title":"Compr Psychiatry."},{"issue":"3","key":"9499_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/acps.13582","volume":"148","author":"M Tournier","year":"2023","unstructured":"Tournier M, Benard-Laribiere A, Jollant F, et al. Risk of suicide attempt and suicide associated with benzodiazepine: A nationwide case crossover study. Acta Psychiatr Scand. 2023;148(3):233-241. https:\/\/doi.org\/10.1111\/acps.13582","journal-title":"Acta Psychiatr Scand."},{"issue":"2","key":"9499_CR13","doi-asserted-by":"publisher","first-page":"02037","DOI":"10.4088\/PCC.16r02037","volume":"19","author":"TJ Dodds","year":"2017","unstructured":"Dodds TJ. Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature. Prim Care Companion CNS Disord. 2017;19(2):16r02037. https:\/\/doi.org\/10.4088\/PCC.16r02037","journal-title":"Prim Care Companion CNS Disord."},{"key":"9499_CR14","first-page":"1","volume":"137","author":"L Santo","year":"2020","unstructured":"Santo L, Rui P, Ashman JJ. Physician office visits at which benzodiazepines were prescribed: findings from 2014-2016 National Ambulatory Medical Care Survey. Natl Health Stat Report. 2020;(137):1-16.","journal-title":"Natl Health Stat Report."},{"issue":"7","key":"9499_CR15","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1017\/s0033291703008213","volume":"33","author":"HV Curran","year":"2003","unstructured":"Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med. 2003;33(7):1223-1237. https:\/\/doi.org\/10.1017\/s0033291703008213","journal-title":"Psychol Med."},{"key":"9499_CR16","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. American Psychiatric Association; 2022:1120.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"9499_CR17","doi-asserted-by":"publisher","unstructured":"Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States. J Clin Psychiatry. 2018;79(6). https:\/\/doi.org\/10.4088\/JCP.18m12174","DOI":"10.4088\/JCP.18m12174"},{"key":"9499_CR18","unstructured":"Department of Justice Announces DEA Seizures of Historic Amounts of Deadly Fentanyl-Laced Fake Pills in Public Safety Surge to Protect U.S. Communities. US Dept of Justice; September 30, 2021. https:\/\/www.justice.gov\/opa\/pr\/department-justice-announces-dea-seizures-historic-amounts-deadly-fentanyl-laced-fake-pills"},{"issue":"1","key":"9499_CR19","doi-asserted-by":"publisher","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","volume":"2","author":"SD Agarwal","year":"2019","unstructured":"Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):e187399-e187399. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.7399","journal-title":"JAMA Netw Open."},{"issue":"Suppl 2","key":"9499_CR20","first-page":"28","volume":"66","author":"CP O\u2019Brien","year":"2005","unstructured":"O\u2019Brien C P. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 Suppl 2:28-33.","journal-title":"J Clin Psychiatry."},{"key":"9499_CR21","doi-asserted-by":"publisher","first-page":"j760","DOI":"10.1136\/bmj.j760","volume":"356","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760. https:\/\/doi.org\/10.1136\/bmj.j760","journal-title":"BMJ."},{"key":"9499_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2698","volume":"350","author":"TW Park","year":"2015","unstructured":"Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698. https:\/\/doi.org\/10.1136\/bmj.h2698","journal-title":"BMJ."},{"key":"9499_CR23","unstructured":"US Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. 2016."},{"issue":"4","key":"9499_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/pm\/pny307","volume":"20","author":"K Kroenke","year":"2019","unstructured":"Kroenke K, Alford DP, Argoff C, et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: a consensus panel report. Pain Med. 2019;20(4):724-735. https:\/\/doi.org\/10.1093\/pm\/pny307","journal-title":"Pain Med."},{"key":"9499_CR25","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. US Food and Drug Administration. 2019. https:\/\/www.fda.gov\/media\/122935\/download?attachment"},{"issue":"5","key":"9499_CR26","doi-asserted-by":"publisher","first-page":"e0232538","DOI":"10.1371\/journal.pone.0232538","volume":"15","author":"PORC Coffin","year":"2020","unstructured":"Coffin PO RC, Oman N, Sinchek K, Santos G-M, Faul M, et al. Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain. PLoS ONE. 2020;15(5):e0232538.","journal-title":"PLoS ONE."},{"issue":"11","key":"9499_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","volume":"89","author":"H P\u00e9tursson","year":"1994","unstructured":"P\u00e9tursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455-1459. https:\/\/doi.org\/10.1111\/j.1360-0443.1994.tb03743.x","journal-title":"Addiction."},{"key":"9499_CR28","unstructured":"GRADE Working Group. Welcome to the GRADE working group. Accessed June 6, 2024, https:\/\/www.gradeworkinggroup.org\/"},{"key":"9499_CR29","unstructured":"RAND. Delphi Method. Accessed June 6, 2024, https:\/\/www.rand.org\/topics\/delphi-method.html"},{"key":"9499_CR30","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, eds. GRADE Handbook. Updated October 2013. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"issue":"1","key":"9499_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002130050422","volume":"134","author":"RR Griffiths","year":"1997","unstructured":"Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse. Psychopharmacology (Berl). 1997;134(1):1-37. https:\/\/doi.org\/10.1007\/s002130050422","journal-title":"Psychopharmacology (Berl)."},{"issue":"1","key":"9499_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.20452\/pamw.4391","volume":"129","author":"JY Lee","year":"2019","unstructured":"Lee JY, Farrell B, Holbrook AM. Deprescribing benzodiazepine receptor agonists taken for insomnia: a review and key messages from practice guidelines. Pol Arch Intern Med. 2019;129(1):43-49. https:\/\/doi.org\/10.20452\/pamw.4391","journal-title":"Pol Arch Intern Med."},{"issue":"5","key":"9499_CR33","first-page":"339","volume":"64","author":"K Pottie","year":"2018","unstructured":"Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.","journal-title":"Can Fam Physician."},{"key":"9499_CR34","doi-asserted-by":"publisher","first-page":"416864","DOI":"10.1155\/2012\/416864","volume":"2012","author":"CH Vinkers","year":"2012","unstructured":"Vinkers CH, Olivier B. Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators? Adv Pharmacol Sci. 2012;2012:416864. https:\/\/doi.org\/10.1155\/2012\/416864","journal-title":"Adv Pharmacol Sci."},{"issue":"7526","key":"9499_CR35","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/bmj.38623.768588.47","volume":"331","author":"J Glass","year":"2005","unstructured":"Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169. https:\/\/doi.org\/10.1136\/bmj.38623.768588.47","journal-title":"BMJ."},{"issue":"2","key":"9499_CR36","first-page":"225","volume":"162","author":"AM Holbrook","year":"2000","unstructured":"Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233.","journal-title":"CMAJ."},{"issue":"3","key":"9499_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jbspin.2019.11.003","volume":"87","author":"TN Poly","year":"2020","unstructured":"Poly TN, Islam MM, Yang HC, Li YJ. Association between benzodiazepines use and risk of hip fracture in the elderly people: a meta-analysis of observational studies. Joint Bone Spine. 2020;87(3):241-249. https:\/\/doi.org\/10.1016\/j.jbspin.2019.11.003","journal-title":"Joint Bone Spine."},{"key":"9499_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejim.2019.10.032","volume":"72","author":"G Rivasi","year":"2020","unstructured":"Rivasi G, Kenny RA, Ungar A, Romero-Ortuno R. Effects of benzodiazepines on orthostatic blood pressure in older people. Eur J Intern Med. 2020;72:73-78. https:\/\/doi.org\/10.1016\/j.ejim.2019.10.032","journal-title":"Eur J Intern Med."},{"issue":"2","key":"9499_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170. https:\/\/doi.org\/10.1111\/bdi.12609","journal-title":"Bipolar Disord."},{"issue":"2","key":"9499_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/15622975.2022.2086295","volume":"24","author":"B Bandelow","year":"2023","unstructured":"Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders \u2013 Version 3. Part I: Anxiety disorders. World J Biol Psychiatry. 2023;24(2):79-117. https:\/\/doi.org\/10.1080\/15622975.2022.2086295","journal-title":"World J Biol Psychiatry."},{"issue":"2","key":"9499_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1176\/appi.focus.20200048","volume":"19","author":"A Melaragno","year":"2021","unstructured":"Melaragno A. Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance. Focus. 2021;19(2):145-160. https:\/\/doi.org\/10.1176\/appi.focus.20200048","journal-title":"Focus."},{"issue":"3","key":"9499_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2165\/00003495-200059030-00006","volume":"59","author":"M Kita","year":"2000","unstructured":"Kita M, Goodkin DE. Drugs Used to Treat Spasticity. Drugs. 2000;59(3):487-495. https:\/\/doi.org\/10.2165\/00003495-200059030-00006","journal-title":"Drugs."},{"issue":"9","key":"9499_CR43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","volume":"36","author":"R Kienitz","year":"2022","unstructured":"Kienitz R, Kay L, Beuchat I, et al. Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability. CNS Drugs. 2022;36(9):951-975. https:\/\/doi.org\/10.1007\/s40263-022-00940-2","journal-title":"CNS Drugs."},{"issue":"2","key":"9499_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40263-023-01060-1","volume":"38","author":"PE Penovich","year":"2024","unstructured":"Penovich PE, Rao VR, Long L, Carrazana E, Rabinowicz AL. Benzodiazepines for the Treatment of Seizure Clusters. CNS Drugs. 2024;38(2):125-140. https:\/\/doi.org\/10.1007\/s40263-023-01060-1","journal-title":"CNS Drugs."},{"issue":"8","key":"9499_CR45","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.5665\/sleep.1986","volume":"35","author":"RN Aurora","year":"2012","unstructured":"Aurora RN, Kristo DA, Bista SR, et al. Update to the AASM Clinical Practice Guideline: \u201cThe treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses\u201d. Sleep. 2012;35(8):1037. https:\/\/doi.org\/10.5665\/sleep.1986","journal-title":"Sleep."},{"issue":"3","key":"9499_CR46","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11920-010-0113-y","volume":"12","author":"A Francis","year":"2010","unstructured":"Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep. 2010;12(3):180-185. https:\/\/doi.org\/10.1007\/s11920-010-0113-y","journal-title":"Curr Psychiatry Rep."},{"key":"9499_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.schres.2023.02.015","volume":"263","author":"D Hirjak","year":"2024","unstructured":"Hirjak D, Fricchione G, Wolf RC, Northoff G. Lorazepam in catatonia - Past, present and future of a clinical success story. Schizophr Res. 2024;263:27-34. https:\/\/doi.org\/10.1016\/j.schres.2023.02.015","journal-title":"Schizophr Res."},{"issue":"5","key":"9499_CR48","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jpainsymman.2014.03.001","volume":"47","author":"P Howard","year":"2014","unstructured":"Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Benzodiazepines. J Pain Symptom Manage. 2014;47(5):955-964. https:\/\/doi.org\/10.1016\/j.jpainsymman.2014.03.001","journal-title":"J Pain Symptom Manage."},{"issue":"12","key":"9499_CR49","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1001\/jamainternmed.2019.4235","volume":"179","author":"ME Tinetti","year":"2019","unstructured":"Tinetti ME, Naik AD, Dindo L, et al. Association of Patient Priorities\u2013Aligned Decision-Making With Patient Outcomes and Ambulatory Health Care Burden Among Older Adults With Multiple Chronic Conditions. JAMA Intern Med. 2019;179(12):1688-1697. https:\/\/doi.org\/10.1001\/jamainternmed.2019.4235","journal-title":"JAMA Intern Med."},{"key":"9499_CR50","doi-asserted-by":"crossref","unstructured":"Ball\u00f3kov\u00e1 AL, Fialov\u00e1 D. Benzodiazepines, Age-Related Pharmacological Changes, and Risk of Falls in Older Adults. Neuropathol Drug Addict Subs Misuse. 2016:334-344.","DOI":"10.1016\/B978-0-12-800634-4.00033-0"},{"issue":"6","key":"9499_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2165\/00023210-200115060-00005","volume":"15","author":"HD Desai","year":"2001","unstructured":"Desai HD, Seabolt J, Jann MW. Smoking in Patients Receiving Psychotropic Medications. CNS Drugs. 2001;15(6):469-494. https:\/\/doi.org\/10.2165\/00023210-200115060-00005","journal-title":"CNS Drugs."},{"issue":"1\u20132","key":"9499_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","volume":"125","author":"JD Jones","year":"2012","unstructured":"Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1-2):8-18. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.07.004","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"9499_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41-57. https:\/\/doi.org\/10.2165\/00003088-200038010-00003","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"9499_CR54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7861\/fhj.2020-0233","volume":"8","author":"DP Gopal","year":"2021","unstructured":"Gopal DP, Chetty U, O\u2019Donnell P, Gajria C, Blackadder-Weinstein J. Implicit bias in healthcare: clinical practice, research and decision making. Future Healthc J. 2021;8(1):40-48. https:\/\/doi.org\/10.7861\/fhj.2020-0233","journal-title":"Future Healthc J."},{"issue":"12","key":"9499_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48557","volume":"6","author":"DT Maust","year":"2023","unstructured":"Maust DT, Petzold K, Strominger J, Kim HM, Bohnert ASB. Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy. JAMA Netw Open. 2023;6(12):e2348557. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.48557","journal-title":"JAMA Netw Open."},{"issue":"6","key":"9499_CR56","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamainternmed.2014.949","volume":"174","author":"C Tannenbaum","year":"2014","unstructured":"Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890-898. https:\/\/doi.org\/10.1001\/jamainternmed.2014.949","journal-title":"JAMA Intern Med."},{"issue":"6","key":"9499_CR57","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1192\/bjp.bp.113.134650","volume":"204","author":"C Vicens","year":"2014","unstructured":"Vicens C, Bejarano F, Sempere E, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Article. Br J Psychiatry. 2014;204(6):471-479. https:\/\/doi.org\/10.1192\/bjp.bp.113.134650","journal-title":"Article. Br J Psychiatry."},{"issue":"2","key":"9499_CR58","first-page":"62","volume":"104","author":"X Hu","year":"2011","unstructured":"Hu X. Benzodiazepine withdrawal seizures and management. J Oklahoma State Med Assoc. 2011;104(2):62-65.","journal-title":"J Oklahoma State Med Assoc"},{"issue":"4","key":"9499_CR59","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/neurolint13040059","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Nix CA, Hollier J, et al. Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int. 2021;13(4):594-607. https:\/\/doi.org\/10.3390\/neurolint13040059","journal-title":"Neurol Int."},{"issue":"4","key":"9499_CR60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/1355621021000005973","volume":"7","author":"G Gerra","year":"2002","unstructured":"Gerra G, Zaimovic A, Giusti F, Moi G, Brewer C. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study. Addict Biol. 2002;7(4):385-95. https:\/\/doi.org\/10.1080\/1355621021000005973","journal-title":"Addict Biol."},{"issue":"11","key":"9499_CR61","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00228-001-0387-4","volume":"57","author":"M Petrovic","year":"2002","unstructured":"Petrovic M, Pevernagie D, Mariman A, Van Maele G, Afschrift M. Fast withdrawal from benzodiazepines in geriatric inpatients: a randomised double-blind, placebo-controlled trial. Eur J Clin Pharmacol. 2002;57(11):759-64. https:\/\/doi.org\/10.1007\/s00228-001-0387-4","journal-title":"Eur J Clin Pharmacol."},{"issue":"1","key":"9499_CR62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/adm.0000000000000350","volume":"12","author":"N Ait-Daoud","year":"2018","unstructured":"Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A review of alprazolam use, misuse, and withdrawal. J Addict Med. 2018;12(1):4-10. https:\/\/doi.org\/10.1097\/adm.0000000000000350","journal-title":"J Addict Med."},{"issue":"4","key":"9499_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000126073","volume":"77","author":"EAG Joosten","year":"2008","unstructured":"Joosten EAG, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CPF, de Jong CAJ. Systematic Review of the Effects of Shared Decision-Making on Patient Satisfaction, Treatment Adherence and Health Status. Psychother Psychosomat. 2008;77(4):219-226. https:\/\/doi.org\/10.1159\/000126073","journal-title":"Psychother Psychosomat."},{"issue":"1","key":"9499_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0272989x14551638","volume":"35","author":"LA Shay","year":"2015","unstructured":"Shay LA, Lafata JE. Where Is the Evidence? A Systematic Review of Shared Decision Making and Patient Outcomes. Med Dec Making. 2015;35(1):114-131. https:\/\/doi.org\/10.1177\/0272989x14551638","journal-title":"Medical Decision Making."},{"issue":"5","key":"9499_CR65","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.socscimed.2005.07.016","volume":"62","author":"JM Parr","year":"2006","unstructured":"Parr JM, Kavanagh DJ, Young RM, McCafferty K. Views of general practitioners and benzodiazepine users on benzodiazepines: a qualitative analysis. Soc Sci Med. 2006;62(5):1237-1249. https:\/\/doi.org\/10.1016\/j.socscimed.2005.07.016","journal-title":"Soc Sci Med."},{"issue":"10","key":"9499_CR66","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40266-013-0106-8","volume":"30","author":"E Reeve","year":"2013","unstructured":"Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793-807. https:\/\/doi.org\/10.1007\/s40266-013-0106-8","journal-title":"Drugs Aging."},{"key":"9499_CR67","doi-asserted-by":"publisher","first-page":"204209862211164","DOI":"10.1177\/20420986221116465","volume":"13","author":"KM Lukacena","year":"2022","unstructured":"Lukacena KM, Keck JW, Freeman PR, Harrington NG, Huffmyer MJ, Moga DC. Patients\u2019 attitudes toward deprescribing and their experiences communicating with clinicians and pharmacists. Ther Adv Drug Saf. 2022;13:20420986221116465. https:\/\/doi.org\/10.1177\/20420986221116465","journal-title":"Ther Adv Drug Saf."},{"issue":"4","key":"9499_CR68","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/08039481003624173","volume":"64","author":"B Vikander","year":"2010","unstructured":"Vikander B, Koechling UM, Borg S, T\u00f6nne U, Hiltunen AJ. Benzodiazepine tapering: A prospective study. Nord J Psychiatry. 2010;64(4):273-282. https:\/\/doi.org\/10.3109\/08039481003624173","journal-title":"Nord J Psychiatry."},{"key":"9499_CR69","unstructured":"National Institutes for Health and Care Excellence. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. 2022."},{"issue":"3","key":"9499_CR70","first-page":"260","volume":"108","author":"S Robertson","year":"2023","unstructured":"Robertson S, Peacock EE, Scott R. Benzodiazepine Use Disorder: Common Questions and Answers. Am Fam Physician. 2023;108(3):260-266.","journal-title":"Am Fam Physician."},{"key":"9499_CR71","unstructured":"US Department of Veterans Affairs. VISN 4: EMPOWER Program. https:\/\/marketplace.va.gov\/innovations\/eliminating-medications-through-patient-ownership-of-end-results"},{"issue":"10","key":"9499_CR72","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","volume":"27","author":"G Elwyn","year":"2012","unstructured":"Elwyn G, Frosch D, Thomson R, et al. Shared Decision Making: A Model for Clinical Practice. J Gen Intern Med. 2012;27(10):1361-1367. https:\/\/doi.org\/10.1007\/s11606-012-2077-6","journal-title":"J Gen Intern Med."},{"issue":"4","key":"9499_CR73","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/gps.4344","volume":"31","author":"TA Jackson","year":"2016","unstructured":"Jackson TA, Wilson D, Richardson S, Lord JM. Predicting outcome in older hospital patients with delirium: a systematic literature review. Int J Geriatr Psychiatry. 2016;31(4):392-399. https:\/\/doi.org\/10.1002\/gps.4344","journal-title":"Int J Geriatr Psychiatry."},{"key":"9499_CR74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.maturitas.2019.08.007","volume":"129","author":"NMS Gol\u00fcke","year":"2019","unstructured":"Gol\u00fcke NMS, van de Vorst IE, Vaartjes IH, et al. Risk factors for in-hospital mortality in patients with dementia. Maturitas. 2019;129:57-61. https:\/\/doi.org\/10.1016\/j.maturitas.2019.08.007","journal-title":"Maturitas."},{"issue":"10","key":"9499_CR75","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1001\/archpsyc.1990.01810220024003","volume":"47","author":"E Schweizer","year":"1990","unstructured":"Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term Therapeutic Use of Benzodiazepines: II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47(10):908-915.","journal-title":"Arch Gen Psychiatry."},{"key":"9499_CR76","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1192\/bjp.182.6.498","volume":"182","author":"RC Oude Voshaar","year":"2003","unstructured":"Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry. 2003;182:498-504. https:\/\/doi.org\/10.1192\/bjp.182.6.498","journal-title":"Br J Psychiatry."},{"issue":"3","key":"9499_CR77","doi-asserted-by":"publisher","first-page":"11481","DOI":"10.1002\/14651858.CD011481.pub2","volume":"3","author":"L Baandrup","year":"2018","unstructured":"Baandrup L, Ebdrup BH, Rasmussen J, Lindschou J, Gluud C, Glenth\u00f8j BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018;3(3):Cd011481. https:\/\/doi.org\/10.1002\/14651858.CD011481.pub2","journal-title":"Cochrane Database Syst Rev."},{"issue":"1\u20132","key":"9499_CR78","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0740-5472(91)90023-4","volume":"8","author":"H Ashton","year":"1991","unstructured":"Ashton H. Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat. 1991;8(1-2):19-28. https:\/\/doi.org\/10.1016\/0740-5472(91)90023-4","journal-title":"J Subst Abuse Treat."},{"issue":"5","key":"9499_CR79","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/add.15695","volume":"117","author":"DS Baldwin","year":"2022","unstructured":"Baldwin DS. Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications. Addiction. 2022;117(5):1472-1482. https:\/\/doi.org\/10.1111\/add.15695","journal-title":"Addiction."},{"key":"9499_CR80","volume-title":"Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual)","author":"CH Ashton","year":"2002","unstructured":"Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002."},{"key":"9499_CR81","volume-title":"Chapter 3: Safe Deprescribing of Benzodiazepines and Z-drugs","author":"M Horowitz","year":"2024","unstructured":"Horowitz M, Taylor DM. Chapter 3: Safe Deprescribing of Benzodiazepines and Z-drugs. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. WILEY Blackwell; 2024."},{"issue":"4","key":"9499_CR82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-2007-979558","volume":"29","author":"S Michelini","year":"1996","unstructured":"Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry. 1996;29(4):127-134. https:\/\/doi.org\/10.1055\/s-2007-979558","journal-title":"Pharmacopsychiatry."},{"key":"9499_CR83","unstructured":"Gold J, Ward K. AAPP Pharmacist Toolkit: Benzodiazepine Taper [Internet]. Lincoln, NE: American Association of Psychiatric Pharmacists, 2022. [revised Sept 26, 2022]. https:\/\/aapp.org\/guideline\/benzo"},{"issue":"4","key":"9499_CR84","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1081\/ja-200052433","volume":"40","author":"H Vorma","year":"2005","unstructured":"Vorma H, Naukkarinen HH, Sarna SJ, Kuoppasalmi KI. Predictors of benzodiazepine discontinuation in subjects manifesting complicated dependence. Subst Use Misuse. 2005;40(4):499-510. https:\/\/doi.org\/10.1081\/ja-200052433","journal-title":"Subst Use Misuse."},{"issue":"2","key":"9499_CR85","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0163-7258(03)00029-9","volume":"98","author":"C Allison","year":"2003","unstructured":"Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther. May 2003;98(2):171-95. https:\/\/doi.org\/10.1016\/s0163-7258(03)00029-9","journal-title":"Pharmacol Ther."},{"key":"9499_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102507","volume":"70","author":"J Brandt","year":"2024","unstructured":"Brandt J, Bressi J, Le ML, et al. Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. EClinicalMedicine. 2024;70:102507. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102507","journal-title":"EClinicalMedicine."},{"key":"9499_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1996","volume":"348","author":"S Weich","year":"2014","unstructured":"Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996. https:\/\/doi.org\/10.1136\/bmj.g1996","journal-title":"BMJ."},{"key":"9499_CR88","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","volume":"174","author":"T Abrahamsson","year":"2017","unstructured":"Abrahamsson T, Berge J, \u00d6jehagen A, H\u00e5kansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.01.013","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"9499_CR89","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12916-020-01821-5","volume":"18","author":"K Richardson","year":"2020","unstructured":"Richardson K, Loke YK, Fox C, et al. Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. BMC Med. 2020;18(1):351. https:\/\/doi.org\/10.1186\/s12916-020-01821-5","journal-title":"BMC Med."},{"key":"9499_CR90","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.sleep.2021.04.032","volume":"83","author":"A Haines","year":"2021","unstructured":"Haines A, Shadyab AH, Saquib N, Kamensky V, Stone K, Wassertheil-Smoller S. The association of hypnotics with incident cardiovascular disease and mortality in older women with sleep disturbances. Sleep Med. 2021;83:304-310. https:\/\/doi.org\/10.1016\/j.sleep.2021.04.032","journal-title":"Sleep Med."},{"issue":"5","key":"9499_CR91","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.sleh.2023.05.006","volume":"9","author":"AA El-Solh","year":"2023","unstructured":"El-Solh AA, Lawson Y, Wilding GE. The risk of major adverse cardiovascular events associated with the use of hypnotics in patients with insomnia. Sleep Health. 2023;9(5):717-725. https:\/\/doi.org\/10.1016\/j.sleh.2023.05.006","journal-title":"Sleep Health."},{"issue":"6","key":"9499_CR92","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40266-018-0544-4","volume":"35","author":"BJ Ng","year":"2018","unstructured":"Ng BJ, Le Couteur DG, Hilmer SN. Deprescribing benzodiazepines in older patients: impact of interventions targeting physicians, pharmacists, and patients. Drugs Aging. 2018;35(6):493-521.","journal-title":"Drugs Aging."},{"issue":"10","key":"9499_CR93","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/j.1552-4604.1989.tb03246.x","volume":"29","author":"DJ Greenblatt","year":"1989","unstructured":"Greenblatt DJ, Shader RI, Harmatz JS. Implications of Altered Drug Disposition in the Elderly: Studies of Benzodiazepines. J Clin Pharmacol. 1989;29(10):866-872. https:\/\/doi.org\/10.1002\/j.1552-4604.1989.tb03246.x","journal-title":"J Clin Pharmacol."},{"issue":"12","key":"9499_CR94","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","volume":"17","author":"JW Wastesson","year":"2018","unstructured":"Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185-1196. https:\/\/doi.org\/10.1080\/14740338.2018.1546841","journal-title":"Expert Opin Drug Saf."},{"key":"9499_CR95","doi-asserted-by":"publisher","unstructured":"Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc (2003). 2017;57(6):729-738.e10. https:\/\/doi.org\/10.1016\/j.japh.2017.06.002","DOI":"10.1016\/j.japh.2017.06.002"},{"key":"9499_CR96","unstructured":"Conn D, Gibson M, McCabe D. National guidelines for seniors\u2019 mental health: the assessment and treatment of mental health issues in long-term care homes (focus on mood and behavior symptoms). Toronto, ON: Canadian Coalition for Seniors\u2019 Mental health; 2014."},{"key":"9499_CR97","unstructured":"Bureau of Justice Assistance. Guidelines for Managing Substance Withdrawal in Jails. 2023. Accessed May 3, 2024. https:\/\/www.cossup.org\/Content\/Documents\/JailResources\/Guidelines_for_Managing_Substance_Withdrawal_in_Jails_6-6-23_508.pdf"},{"issue":"9","key":"9499_CR98","first-page":"606","volume":"96","author":"CI Ogbonna","year":"2017","unstructured":"Ogbonna CI, Lembke A. Tapering patients off of benzodiazepines. Am Fam Physician. 2017;96(9):606-610.","journal-title":"Am Fam Physician."},{"issue":"4","key":"9499_CR99","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.smrv.2009.10.008","volume":"14","author":"MA Mets","year":"2010","unstructured":"Mets MA, Volkerts ER, Olivier B, Verster JC. Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev. 2010;14(4):259-267. https:\/\/doi.org\/10.1016\/j.smrv.2009.10.008","journal-title":"Sleep Med Rev."},{"key":"9499_CR100","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. 2020. https:\/\/www.fda.gov\/media\/142368\/download"},{"issue":"5","key":"9499_CR101","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","volume":"38","author":"J Brett","year":"2015","unstructured":"Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152-155. https:\/\/doi.org\/10.18773\/austprescr.2015.055","journal-title":"Aust Prescr."},{"issue":"2","key":"9499_CR102","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1017\/S0790966700008909","volume":"22","author":"B Raju","year":"2005","unstructured":"Raju B, Meagher D. Patient-controlled benzodiazepine dose reduction in a community mental health service. Ir J Psychol Med. 2005;22(2):42-45. https:\/\/doi.org\/10.1017\/S0790966700008909","journal-title":"Ir J Psychol Med."},{"issue":"3","key":"9499_CR103","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12529-021-10002-4","volume":"29","author":"VV Barros","year":"2022","unstructured":"Barros VV, Opaleye ES, Demarzo M, et al. Effects of mindfulness-based relapse prevention on the chronic use of hypnotics in treatment-seeking women with insomnia: a randomized controlled trial. Int J Behav Med. 2022;29(3):266-277. https:\/\/doi.org\/10.1007\/s12529-021-10002-4","journal-title":"Int J Behav Med."},{"issue":"1","key":"9499_CR104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/add.15997","volume":"118","author":"A Soni","year":"2022","unstructured":"Soni A, Thiyagarajan A, Reeve J. Feasibility and effectiveness of deprescribing benzodiazepines and z-drugs: systematic review and meta-analysis. Addiction. 2022;118(1):7-16.","journal-title":"Addiction."},{"key":"9499_CR105","doi-asserted-by":"publisher","first-page":"009652","DOI":"10.1002\/14651858.CD009652.pub2","volume":"5","author":"CD Darker","year":"2015","unstructured":"Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015;(5):Cd009652. https:\/\/doi.org\/10.1002\/14651858.CD009652.pub2","journal-title":"Cochrane Database Syst Rev."},{"issue":"9","key":"9499_CR106","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/add.14981","volume":"115","author":"T Lynch","year":"2020","unstructured":"Lynch T, Ryan C, Hughes CM, et al. Brief interventions targeting long\u2010term benzodiazepine and Z\u2010drug use in primary care: a systematic review and meta\u2010analysis. Addiction. 2020;115(9):1618-1639.","journal-title":"Addiction."},{"issue":"6","key":"9499_CR107","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/bcp.12294","volume":"77","author":"R L\u00e4hteenm\u00e4ki","year":"2014","unstructured":"L\u00e4hteenm\u00e4ki R, Puustinen J, Vahlberg T, et al. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77(6):975-985. https:\/\/doi.org\/10.1111\/bcp.12294","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"9499_CR108","first-page":"57","volume":"99","author":"L Croke","year":"2019","unstructured":"Croke L. Deprescribing benzodiazepine receptor agonists for insomina in adults. Am Fam Physician. 2019;99(1):57-58.","journal-title":"Am Fam Physician."},{"issue":"3","key":"9499_CR109","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1037\/ser0000332","volume":"16","author":"A Klee","year":"2019","unstructured":"Klee A, Chinman M, Kearney L. Peer specialist services: new frontiers and new roles. Psychol Serv. 2019;16(3):353-359. https:\/\/doi.org\/10.1037\/ser0000332","journal-title":"Psychol Serv."},{"issue":"12","key":"9499_CR110","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1176\/ajp.151.12.1760","volume":"151","author":"ECV Klein","year":"1994","unstructured":"Klein E CV, Stolk J, Lenox RH. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry. 1994;151(12):1760-1766.","journal-title":"Am J Psychiatry."},{"issue":"5","key":"9499_CR111","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/archpsyc.1991.01810290060012","volume":"48","author":"E Schweizer","year":"1991","unstructured":"Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Arch Gen Psychiatry. 1991;48(5):448-452.","journal-title":"Arch Gen Psychiatry."},{"key":"9499_CR112","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.drugalcdep.2018.04.028","volume":"189","author":"JW Welsh","year":"2018","unstructured":"Welsh JW, Tretyak V, McHugh RK, Weiss RD, Bogunovic O. Review: adjunctive pharmacologic approaches for benzodiazepine tapers. Drug Alcohol Depend. 2018;189:96-107. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.04.028","journal-title":"Drug Alcohol Depend."},{"key":"9499_CR113","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1192\/bjp.157.2.232","volume":"157","author":"CH Ashton","year":"1990","unstructured":"Ashton CH, Rawlins MD, Tyrer SP. A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry. 1990;157:232-8. https:\/\/doi.org\/10.1192\/bjp.157.2.232","journal-title":"Br J Psychiatry."},{"issue":"1","key":"9499_CR114","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00004714-198702000-00003","volume":"7","author":"M Lader","year":"1987","unstructured":"Lader M, Olajide D. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol. 1987;7(1):11-15.","journal-title":"J Clin Psychopharmacol."},{"issue":"4","key":"9499_CR115","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/026988119500900407","volume":"9","author":"S Morton","year":"1995","unstructured":"Morton S, Lader M. Buspirone treatment as an aid to benzodiazepine withdrawal. J Psychopharmacol. 1995;9(4):331-335.","journal-title":"J Psychopharmacol."},{"key":"9499_CR116","first-page":"46","volume":"51","author":"HD Udelman","year":"1990","unstructured":"Udelman HD, Udelman DL. Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. J Clin Psychiatry. 1990;51:46-50.","journal-title":"The Journal of Clinical Psychiatry."},{"issue":"12","key":"9499_CR117","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1176\/appi.ajp.157.12.1973","volume":"157","author":"K Rickels","year":"2000","unstructured":"Rickels K, DeMartinis N, Garc\u00eda-Espa\u00f1a F, Greenblatt DJ, Mandos LA, Rynn M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry. 2000;157(12):1973-9. https:\/\/doi.org\/10.1176\/appi.ajp.157.12.1973","journal-title":"Am J Psychiatry."},{"issue":"5","key":"9499_CR118","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/01.jcp.0000088907.24613.3f","volume":"23","author":"M Rynn","year":"2003","unstructured":"Rynn M, Garcia-Espana F, Greenblatt DJ, Mandos LA, Schweizer E, Rickels K. Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. J Clin Psychopharmacol. 2003;23(5):505-8. https:\/\/doi.org\/10.1097\/01.jcp.0000088907.24613.3f","journal-title":"J Clin Psychopharmacol."},{"issue":"6","key":"9499_CR119","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00004714-198912000-00005","volume":"9","author":"UE Busto","year":"1989","unstructured":"Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol. 1989;9(6):412-416.","journal-title":"J Clin Psychopharmacol."},{"issue":"1","key":"9499_CR120","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0165-0327(90)90009-w","volume":"19","author":"P Tyrer","year":"1990","unstructured":"Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord. 1990;19(1):53-61. https:\/\/doi.org\/10.1016\/0165-0327(90)90009-w","journal-title":"J Affect Disord."},{"issue":"6","key":"9499_CR121","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s11739-022-02976-0","volume":"17","author":"S Sartori","year":"2022","unstructured":"Sartori S, Crescioli G, Brilli V, et al. Phenobarbital use in benzodiazepine and z-drug detoxification: a single-centre 15-year observational retrospective study in clinical practice. Intern Emerg Med. 2022;17(6):1631-1640. https:\/\/doi.org\/10.1007\/s11739-022-02976-0","journal-title":"Intern Emerg Med."},{"issue":"2","key":"9499_CR122","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/ADM.0000000000001071","volume":"17","author":"JC Messinger","year":"2023","unstructured":"Messinger JC, Hakimi E, Vercollone L. The Use of a Single Dose of Phenobarbital for Inpatient Management of Benzodiazepine Withdrawal: A Case Report. J Addict Med. 2023;17(2):230-232. https:\/\/doi.org\/10.1097\/ADM.0000000000001071","journal-title":"J Addict Med."},{"issue":"3","key":"9499_CR123","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jsat.2011.12.011","volume":"43","author":"SS Kawasaki","year":"2012","unstructured":"Kawasaki SS, Jacapraro JS, Rastegar DA. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. J Subst Abuse Treat. 2012;43(3):331-334. https:\/\/doi.org\/10.1016\/j.jsat.2011.12.011","journal-title":"J Subst Abuse Treat."},{"key":"9499_CR124","doi-asserted-by":"publisher","unstructured":"Gallo A, MacDonald T, Bennett K, Basso-Hulse G, Hulse G. Is the precipitation of anxiety symptoms associated with bolus doses of flumazenil a barrier to its use at low continuous doses in benzodiazepine withdrawal? Article. J Clin Med. 2022;11(19). https:\/\/doi.org\/10.3390\/jcm11195948","DOI":"10.3390\/jcm11195948"},{"key":"9499_CR125","doi-asserted-by":"publisher","unstructured":"MacDonald T, Gallo AT, Basso-Hulse G, Bennett KS, Hulse GK. A double-blind randomised crossover trial of low-dose flumazenil for benzodiazepine withdrawal: A proof of concept. Article. Drug Alcohol Depend. 2022;236. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109501","DOI":"10.1016\/j.drugalcdep.2022.109501"},{"issue":"16","key":"9499_CR126","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1161\/CIR.0000000000001161","volume":"148","author":"EJ Lavonas","year":"2023","unstructured":"Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoning: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2023;148(16):e149-e184. https:\/\/doi.org\/10.1161\/CIR.0000000000001161","journal-title":"Circulation."},{"key":"9499_CR127","doi-asserted-by":"publisher","unstructured":"Garel N, Greenway KT, Dinh-Williams L-AL, et al. Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. Neuropsychopharmacology. 2023;48(12):1769-1777. https:\/\/doi.org\/10.1038\/s41386-023-01689-y","DOI":"10.1038\/s41386-023-01689-y"},{"key":"9499_CR128","doi-asserted-by":"publisher","first-page":"204512532210823","DOI":"10.1177\/20451253221082386","volume":"12","author":"AJ Reid Finlayson","year":"2022","unstructured":"Reid Finlayson AJ, Macoubrie J, Huff C, Foster DE, Martin PR. Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Ther Adv Psychopharmacol. 2022;12:20451253221082386. https:\/\/doi.org\/10.1177\/20451253221082386","journal-title":"Ther Adv Psychopharmacol."},{"issue":"3","key":"9499_CR129","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3928\/0048-5713-19950301-11","volume":"25","author":"CH Ashton","year":"1995","unstructured":"Ashton CH. Protracted Withdrawal From Benzodiazepines: The Post-Withdrawal Syndrome. Psychiatr Ann. 1995;25(3):174-179.","journal-title":"Psychiatr Ann."},{"issue":"5","key":"9499_CR130","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000506868","volume":"89","author":"F Cosci","year":"2020","unstructured":"Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom. 2020;89(5):283-306. https:\/\/doi.org\/10.1159\/000506868","journal-title":"Psychother Psychosom."},{"issue":"13","key":"9499_CR131","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1177\/1049732317728053","volume":"27","author":"AM Fixsen","year":"2017","unstructured":"Fixsen AM, Ridge D. Stories of hell and healing: internet users\u2019 construction of benzodiazepine distress and withdrawal. Qual Health Res. 2017;27(13):2030-2041. https:\/\/doi.org\/10.1177\/1049732317728053","journal-title":"Qual Health Res."},{"key":"9499_CR132","doi-asserted-by":"publisher","first-page":"204512532211455","DOI":"10.1177\/20451253221145561","volume":"13","author":"C Huff","year":"2023","unstructured":"Huff C, Reid Finlayson AJ, Foster DE, Martin PR. Enduring neurological sequelae of benzodiazepine use: an Internet survey. Ther Adv Psychopharmacol. 2023;13:20451253221145561. https:\/\/doi.org\/10.1177\/20451253221145561","journal-title":"Ther Adv Psychopharmacol."},{"issue":"6","key":"9499_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285584","volume":"18","author":"AD Ritvo","year":"2023","unstructured":"Ritvo AD, Foster DE, Huff C, Reid Finlayson AJ, Silvernail B, Martin PR. Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PLoS One. 2023;18(6):e0285584. https:\/\/doi.org\/10.1371\/journal.pone.0285584","journal-title":"PLoS One."},{"issue":"23","key":"9499_CR134","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMra1807054","volume":"380","author":"KM Babu","year":"2019","unstructured":"Babu KM, Brent J, Juurlink DN. Prevention of Opioid Overdose. N Engl J Med. 2019;380(23):2246-2255. https:\/\/doi.org\/10.1056\/NEJMra1807054","journal-title":"N Engl J Med."},{"issue":"8","key":"9499_CR135","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/pme.12777","volume":"16","author":"B Zedler","year":"2015","unstructured":"Zedler B, Xie L, Wang L, et al. Development of a Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in Veterans\u2019 Health Administration Patients. Pain Med. 2015;16(8):1566-1579. https:\/\/doi.org\/10.1111\/pme.12777","journal-title":"Pain Med."},{"issue":"1","key":"9499_CR136","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/pm\/pnx009","volume":"19","author":"BK Zedler","year":"2018","unstructured":"Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. Validation of a Screening Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in a US Commercial Health Plan Claims Database. Pain Med. 2018;19(1):68-78. https:\/\/doi.org\/10.1093\/pm\/pnx009","journal-title":"Pain Med."},{"issue":"4","key":"9499_CR137","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pmrj.2018.09.026","volume":"11","author":"J Simon","year":"2019","unstructured":"Simon J, Gehret J, Stolzenberg D, et al. Concomitant Use of Opioids and Benzodiazepines in the Outpatient Setting. PM&R. 2019;11(4):337-343. https:\/\/doi.org\/10.1016\/j.pmrj.2018.09.026","journal-title":"PM&R."},{"issue":"2","key":"9499_CR138","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/pme.12594","volume":"16","author":"S Nielsen","year":"2015","unstructured":"Nielsen S, Lintzeris N, Bruno R, et al. Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Med. 2015;16(2):356-366. https:\/\/doi.org\/10.1111\/pme.12594","journal-title":"Pain Med."},{"key":"9499_CR139","doi-asserted-by":"publisher","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022. 2022;71(No. RR-3):1-95. https:\/\/doi.org\/10.15585\/mmwr.rr7103a1","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"9499_CR140","unstructured":"Department of Veterans Affiars, Department of Defense. VA\/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. 2021."},{"key":"9499_CR141","unstructured":"Waller RC, Boyle MP, Daviss SR, et al, eds. The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-occurring Conditions, Volume 1: Adults. 4th ed. Hazelden Publishing; 2023."},{"issue":"5","key":"9499_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2625","volume":"32","author":"SE McCabe","year":"2017","unstructured":"McCabe SE, West BT, Jutkiewicz EM, Boyd CJ. Multiple DSM-5 substance use disorders: A national study of US adults. Hum Psychopharmacol. 2017;32(5):e2625. https:\/\/doi.org\/10.1002\/hup.2625","journal-title":"Hum Psychopharmacol."},{"key":"9499_CR143","volume-title":"New benzodiazepines in Europe - a review","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2021","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. New benzodiazepines in Europe - a review. Luxembourg: Publications Office of the European Union; 2021."},{"key":"9499_CR144","unstructured":"Center for Substance Use Addiction and Health Research. DEA Emerging Threat Reports. Updated 04\/20\/2023. Accessed October 1, 2024. https:\/\/cesar.umd.edu\/publications\/dea-emerging-threat-reports"},{"key":"9499_CR145","doi-asserted-by":"publisher","unstructured":"American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1-91. https:\/\/doi.org\/10.1097\/adm.0000000000000633","DOI":"10.1097\/adm.0000000000000633"},{"issue":"7","key":"9499_CR146","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0269881112444324","volume":"26","author":"AR Lingford-Hughes","year":"2012","unstructured":"Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26(7):899-952. https:\/\/doi.org\/10.1177\/0269881112444324","journal-title":"J Psychopharmacol."},{"issue":"3","key":"9499_CR147","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/ADM.0000000000000323","volume":"11","author":"American Society of Addiction Medicine","year":"2017","unstructured":"American Society of Addiction Medicine. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017;11(3):163-173. https:\/\/doi.org\/10.1097\/ADM.0000000000000323","journal-title":"J Addict Med."},{"key":"9499_CR148","unstructured":"Mayo Clinic Laboratories. Benzodiazepines. Accessed June 13, 2024, https:\/\/qa.backend.mayocliniclabs.com\/test-info\/drug-book\/benzodiazepines.html#:~:text=Benzodiazepines%20are%20extensively%20metabolized%2C%20and,be%20detected%20after%20diazepam%20use.&text=Chlordiazepoxide%20is%20metabolized%20to%20nordiazepam,be%20detected%20after%20chlordiazepoxide%20use."},{"key":"9499_CR149","unstructured":"Substance Abuse and Mental Health Services Administration. Substance Abuse and Mental Health Services Administration: Harm Reduction Framework. 2023. https:\/\/www.samhsa.gov\/sites\/default\/files\/harm-reduction-framework.pdf"},{"issue":"6477","key":"9499_CR150","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/bmj.290.6477.1246","volume":"290","author":"KG Power","year":"1985","unstructured":"Power KG, Jerrom DW, Simpson RJ, Mitchell M. Controlled study of withdrawal symptoms and rebound anxiety after six week course of diazepam for generalised anxiety. Br Med J (Clin Res Ed). 1985;290(6477):1246-1248. https:\/\/doi.org\/10.1136\/bmj.290.6477.1246","journal-title":"Br Med J (Clin Res Ed)."},{"issue":"1","key":"9499_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40271-016-0182-z","volume":"10","author":"C Sirdifield","year":"2017","unstructured":"Sirdifield C, Chipchase SY, Owen S, Siriwardena AN. A systematic review and meta-synthesis of patients\u2019 experiences and perceptions of seeking and using benzodiazepines and z-drugs: towards safer prescribing. Patient. 2017;10(1):1-15.","journal-title":"Patient."},{"issue":"3","key":"9499_CR152","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/13607860410001669778","volume":"8","author":"S Iliffe","year":"2004","unstructured":"Iliffe S, Curran HV, Collins R, Yuen Kee SC, Fletcher S, Woods B. Attitudes to long-term use of benzodiazepine hypnotics by older people in general practice: findings from interviews with service users and providers. Aging Ment Health. 2004;8(3):242-248. https:\/\/doi.org\/10.1080\/13607860410001669778","journal-title":"Aging Ment Health."},{"issue":"Suppl 1","key":"9499_CR153","first-page":"27","volume":"4","author":"DG Dikeos","year":"2002","unstructured":"Dikeos DG, Soldatos CR. The pharmacotherapy of insomnia: efficacy and rebound with hypnotic drugs. Prim Care Companion J Clin Psychiatry. 2002;4(Suppl 1):27-32.","journal-title":"Prim Care Companion J Clin Psychiatry."},{"issue":"4","key":"9499_CR154","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/0278-5846(83)90043-X","volume":"7","author":"G Chouinard","year":"1983","unstructured":"Chouinard G, Labonte A, Fontaine R, Annable L. New concepts in benzodiazepine therapy: Rebound anxiety and new indications for the more potent benzodiazepines. Prog in Neuropsychopharmacology Biol Psychiatry. 1983;7(4):669-673. https:\/\/doi.org\/10.1016\/0278-5846(83)90043-X","journal-title":"Prog in Neuropsychopharmacology Biol Psychiatry."},{"issue":"1","key":"9499_CR155","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1360-0443.2008.02364.x","volume":"104","author":"JM Parr","year":"2009","unstructured":"Parr JM, Kavanagh DJ, Cahill L, Mitchell G, Mc DYR. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2009;104(1):13-24. https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02364.x","journal-title":"Addiction."},{"issue":"4","key":"9499_CR156","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/pcn.13195","volume":"75","author":"M Takeshima","year":"2021","unstructured":"Takeshima M, Otsubo T, Funada D, et al. Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and meta-analysis. Psychiatry Clin Neurosci. 2021;75(4):119-127. https:\/\/doi.org\/10.1111\/pcn.13195","journal-title":"Psychiatry Clin Neurosci."},{"key":"9499_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2019.101214","volume":"48","author":"Y Takaesu","year":"2019","unstructured":"Takaesu Y, Utsumi T, Okajima I, et al. Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2019;48:101214. https:\/\/doi.org\/10.1016\/j.smrv.2019.101214","journal-title":"Sleep Med Rev."},{"issue":"12","key":"9499_CR158","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, et al. The Columbia\u2013Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"9499_CR159","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.psym.2020.04.008","volume":"61","author":"LM Horowitz","year":"2020","unstructured":"Horowitz LM, Snyder DJ, Boudreaux ED, et al. Validation of the Ask Suicide-Screening Questions for Adult Medical Inpatients: A Brief Tool for All Ages. Psychosomatics. 2020;61(6):713-722. https:\/\/doi.org\/10.1016\/j.psym.2020.04.008","journal-title":"Psychosomatics"},{"key":"9499_CR160","unstructured":"Popish SJ, Wells DL. Re-evaluating the Use of Benzodiazepines, A VA Clinician\u2019s Guide. 2016."},{"issue":"6","key":"9499_CR161","first-page":"236","volume":"51","author":"P Braun","year":"1990","unstructured":"Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990;51(6):236-238.","journal-title":"J Clin Psychiatry."},{"issue":"9","key":"9499_CR162","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1345\/aph.1E043","volume":"38","author":"ME Cates","year":"2004","unstructured":"Cates ME, Bishop MH, Davis LL, Lowe JS, Woolley TW. Clonazepam for Treatment of Sleep Disturbances Associated with Combat-Related Posttraumatic Stress Disorder. Ann Pharmacother. 2004;38(9):1395-1399. https:\/\/doi.org\/10.1345\/aph.1E043","journal-title":"Ann Pharmacother."},{"issue":"4","key":"9499_CR163","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/pra.0000000000000091","volume":"21","author":"J Guina","year":"2015","unstructured":"Guina J, Rossetter SR, De RB, Nahhas RW, Welton RS. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pract. 2015;21(4):281-303. https:\/\/doi.org\/10.1097\/pra.0000000000000091","journal-title":"J Psychiatr Pract."},{"issue":"7","key":"9499_CR164","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S2215-0366(20)30136-X","volume":"7","author":"D Freeman","year":"2020","unstructured":"Freeman D, Sheaves B, Waite F, Harvey AG, Harrison PJ. Sleep disturbance and psychiatric disorders. Lancet Psychiatry. 2020;7(7):628-637. https:\/\/doi.org\/10.1016\/S2215-0366(20)30136-X","journal-title":"Lancet Psychiatry."},{"key":"9499_CR165","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cpr.2015.09.001","volume":"42","author":"S Reeve","year":"2015","unstructured":"Reeve S, Sheaves B, Freeman D. The role of sleep dysfunction in the occurrence of delusions and hallucinations: A systematic review. Clin Psychol Rev. 2015;42:96-115. https:\/\/doi.org\/10.1016\/j.cpr.2015.09.001","journal-title":"Clin Psychol Rev."},{"key":"9499_CR166","doi-asserted-by":"publisher","unstructured":"Chapoutot M, Peter-Derex L, Bastuji H, et al. Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders. Int J Environ Res Public Health. 2021;18(19)https:\/\/doi.org\/10.3390\/ijerph181910222","DOI":"10.3390\/ijerph181910222"},{"key":"9499_CR167","unstructured":"2022 NSDUH Detailed Tables. National Survey on Drug Use and Health, https:\/\/www.samhsa.gov\/data\/report\/2022-nsduh-detailed-tables"},{"issue":"7","key":"9499_CR168","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2023","unstructured":"2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. https:\/\/doi.org\/10.1111\/jgs.18372","journal-title":"J Am Geriatr Soc."},{"issue":"1","key":"9499_CR169","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13012-022-01206-7","volume":"17","author":"P Evrard","year":"2022","unstructured":"Evrard P, P\u00e9tein C, Beuscart JB, Spinewine A. Barriers and enablers for deprescribing benzodiazepine receptor agonists in older adults: a systematic review of qualitative and quantitative studies using the theoretical domains framework. Implement Sci. 2022;17(1):41. https:\/\/doi.org\/10.1186\/s13012-022-01206-7","journal-title":"Implement Sci."},{"key":"9499_CR170","doi-asserted-by":"publisher","unstructured":"Rasmussen AF, Poulsen SS, Oldenburg LIK, Vermehren C. The barriers and facilitators of different stakeholders when deprescribing benzodiazepine receptor agonists in older patients-a systematic review. Metabolites. 2021;11(4)https:\/\/doi.org\/10.3390\/metabo11040254","DOI":"10.3390\/metabo11040254"},{"issue":"2","key":"9499_CR171","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/gerona\/glr118","volume":"67","author":"AJ McLachlan","year":"2012","unstructured":"McLachlan AJ, Pont LG. Drug metabolism in older people--a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci. 2012;67(2):175-180. https:\/\/doi.org\/10.1093\/gerona\/glr118","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"11","key":"9499_CR172","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","volume":"91","author":"M Markota","year":"2016","unstructured":"Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc. 2016;91(11):1632-1639. https:\/\/doi.org\/10.1016\/j.mayocp.2016.07.024","journal-title":"Mayo Clin Proc."},{"issue":"1","key":"9499_CR173","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12877-017-0432-5","volume":"17","author":"P Martin","year":"2017","unstructured":"Martin P, Tannenbaum C. Use of the EMPOWER brochure to deprescribe sedative-hypnotic drugs in older adults with mild cognitive impairment. BMC Geriatr. 2017;17(1):37. https:\/\/doi.org\/10.1186\/s12877-017-0432-5","journal-title":"BMC Geriatr."},{"issue":"9","key":"9499_CR174","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/gps.4919","volume":"33","author":"C Fogg","year":"2018","unstructured":"Fogg C, Griffiths P, Meredith P, Bridges J. Hospital outcomes of older people with cognitive impairment: An integrative review. Int J Geriatr Psychiatry. 2018;33(9):1177-1197. https:\/\/doi.org\/10.1002\/gps.4919","journal-title":"Int J Geriatr Psychiatry."},{"issue":"9","key":"9499_CR175","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/brainsci9090235","volume":"9","author":"CE Creeley","year":"2019","unstructured":"Creeley CE, Denton LK. Use of prescribed psychotropics during pregnancy: a systematic review of pregnancy, neonatal, and childhood outcomes. Brain Sci. 2019;9(9):235. https:\/\/doi.org\/10.3390\/brainsci9090235","journal-title":"Brain Sci."},{"issue":"4","key":"9499_CR176","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1001\/jamapsychiatry.2023.4912","volume":"81","author":"LC Meng","year":"2024","unstructured":"Meng LC, Lin CW, Chuang HM, Chen LK, Hsiao FY. Benzodiazepine use during pregnancy and risk of miscarriage. JAMA Psychiatry. 2024;81(4):366-373. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4912","journal-title":"JAMA Psychiatry."},{"key":"9499_CR177","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.genhosppsych.2018.05.010","volume":"53","author":"MP Freeman","year":"2018","unstructured":"Freeman MP, G\u00f3ez-Mogoll\u00f3n L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: Results from a prospective registry of women with psychiatric disorders. Gen Hosp Psychiatry. 2018;53:73-79. https:\/\/doi.org\/10.1016\/j.genhosppsych.2018.05.010","journal-title":"Gen Hosp Psychiatry."},{"issue":"1","key":"9499_CR178","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.genhosppsych.2012.09.003","volume":"35","author":"C Bellantuono","year":"2013","unstructured":"Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013;35(1):3-8. https:\/\/doi.org\/10.1016\/j.genhosppsych.2012.09.003","journal-title":"Gen Hosp Psychiatry."},{"issue":"8","key":"9499_CR179","first-page":"213","volume":"64","author":"JN Lind","year":"2015","unstructured":"Lind JN, Petersen EE, Lederer PA, et al. Infant and maternal characteristics in neonatal abstinence syndrome--selected hospitals in Florida, 2010-2011. MMWR Morb Mortal Wkly Rep. 2015;64(8):213-216.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"9499_CR180","doi-asserted-by":"publisher","unstructured":"Swortfiguer D, Cissoko H, Giraudeau B, Jonville-B\u00e9ra AP, Bensouda L, Autret-Leca E. [Neonatal consequences of benzodiazepines used during the last month of pregnancy]. Arch Pediatr. 2005;12(9):1327-1331. Retentissement n\u00e9onatal de l\u2019exposition aux benzodiaz\u00e9pines en fin de grossesse. https:\/\/doi.org\/10.1016\/j.arcped.2005.03.055","DOI":"10.1016\/j.arcped.2005.03.055"},{"issue":"16","key":"9499_CR181","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.3390\/ijerph20166565","volume":"20","author":"G Eleftheriou","year":"2023","unstructured":"Eleftheriou G, Zandonella Callegher R, Butera R, et al. Consensus panel recommendations for the pharmacological management of pregnant women with depressive disorders. Int J Environ Res Public Health. 2023;20(16):6565. https:\/\/doi.org\/10.3390\/ijerph20166565","journal-title":"Int J Environ Res Public Health."},{"issue":"6","key":"9499_CR182","doi-asserted-by":"publisher","first-page":"579.e1","DOI":"10.1016\/j.ajog.2009.06.061","volume":"201","author":"R Calderon-Margalit","year":"2009","unstructured":"Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol. 2009;201(6):579.e1-8. https:\/\/doi.org\/10.1016\/j.ajog.2009.06.061","journal-title":"Am J Obstet Gynecol."},{"issue":"6270","key":"9499_CR183","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.282.6270.1106","volume":"282","author":"AG Whitelaw","year":"1981","unstructured":"Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. Br Med J (Clin Res Ed). 1981;282(6270):1106-1108. https:\/\/doi.org\/10.1136\/bmj.282.6270.1106","journal-title":"Br Med J (Clin Res Ed)."},{"issue":"10","key":"9499_CR184","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s40264-016-0435-8","volume":"39","author":"I Convertino","year":"2016","unstructured":"Convertino I, Sansone AC, Marino A, et al. Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. Drug Saf. 2016;39(10):903-924. https:\/\/doi.org\/10.1007\/s40264-016-0435-8","journal-title":"Drug Saf."},{"key":"9499_CR185","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2147\/ndt.S36394","volume":"9","author":"N Kieviet","year":"2013","unstructured":"Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat. 2013;9:1257-66. https:\/\/doi.org\/10.2147\/ndt.S36394","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"6","key":"9499_CR186","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1097\/aog.0000000000005202","volume":"141","author":"American College of Obstetricians and Gynecologists","year":"2023","unstructured":"American College of Obstetricians and Gynecologists. Treatment and management of mental health conditions during pregnancy and postpartum: ACOG clinical practice guideline no. 5. Obstet Gynecol. 2023;141(6):1262-1288. https:\/\/doi.org\/10.1097\/aog.0000000000005202","journal-title":"Obstet Gynecol."},{"issue":"3","key":"9499_CR187","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00737-022-01226-8","volume":"25","author":"L Palagini","year":"2022","unstructured":"Palagini L, Bramante A, Baglioni C, et al. Insomnia evaluation and treatment during peripartum: a joint position paper from the European Insomnia Network task force \u201cSleep and Women,\u201d the Italian Marce Society and international experts task force for perinatal mental health. Arch Womens Ment Health. 2022;25(3):561-575. https:\/\/doi.org\/10.1007\/s00737-022-01226-8","journal-title":"Arch Womens Ment Health."},{"issue":"2","key":"9499_CR188","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00737-013-0388-1","volume":"17","author":"P Gopalan","year":"2014","unstructured":"Gopalan P, Glance JB, Azzam PN. Managing benzodiazepine withdrawal during pregnancy: case-based guidelines. Arch Womens Ment Health. 2014;17(2):167-170. https:\/\/doi.org\/10.1007\/s00737-013-0388-1","journal-title":"Arch Womens Ment Health."},{"key":"9499_CR189","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.genhosppsych.2018.12.005","volume":"57","author":"P Gopalan","year":"2019","unstructured":"Gopalan P, Moses-Kolko E, Valpey R, Shenai N, Smith E. Benzodiazepine withdrawal in pregnant women with opioid use disorders: an observational study of current clinical practices at a tertiary obstetrical hospital. Gen Hosp Psychiatry. 2019;57:29-33. https:\/\/doi.org\/10.1016\/j.genhosppsych.2018.12.005","journal-title":"Gen Hosp Psychiatry."},{"issue":"2","key":"9499_CR190","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1542\/peds.2013-3524","volume":"134","author":"P Kocherlakota","year":"2014","unstructured":"Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134(2):e547-e561. https:\/\/doi.org\/10.1542\/peds.2013-3524","journal-title":"Pediatrics."},{"key":"9499_CR191","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jpba.2019.02.011","volume":"168","author":"A Furugen","year":"2019","unstructured":"Furugen A, Nishimura A, Kobayashi M, Umazume T, Narumi K, Iseki K. Quantification of eight benzodiazepines in human breastmilk and plasma by liquid-liquid extraction and liquid-chromatography tandem mass spectrometry: application to evaluation of alprazolam transfer into breastmilk. J Pharm Biomed Anal. 2019;168:83-93. https:\/\/doi.org\/10.1016\/j.jpba.2019.02.011","journal-title":"J Pharm Biomed Anal."},{"issue":"5","key":"9499_CR192","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/bfm.2020.0259","volume":"16","author":"A Nishimura","year":"2021","unstructured":"Nishimura A, Furugen A, Umazume T, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. Breastfeed Med. 2021;16(5):424-431. https:\/\/doi.org\/10.1089\/bfm.2020.0259","journal-title":"Breastfeed Med."},{"issue":"6","key":"9499_CR193","doi-asserted-by":"publisher","first-page":"e1163","DOI":"10.1542\/peds.2005-1561","volume":"117","author":"ME Abdel-Latif","year":"2006","unstructured":"Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 2006;117(6):e1163-e1169. https:\/\/doi.org\/10.1542\/peds.2005-1561","journal-title":"Pediatrics."},{"issue":"5","key":"9499_CR194","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/archpedi.154.5.474","volume":"154","author":"NM Lvoff","year":"2000","unstructured":"Lvoff NM, Lvoff V, Klaus MH. Effect of the baby-friendly initiative on infant abandonment in a Russian hospital. Arch Pediatr Adolesc Med. 2000;154(5):474-477. https:\/\/doi.org\/10.1001\/archpedi.154.5.474","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"6","key":"9499_CR195","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.genhosppsych.2015.06.004","volume":"37","author":"SM Peters","year":"2015","unstructured":"Peters SM, Knauf KQ, Derbidge CM, Kimmel R, Vannoy S. Demographic and clinical factors associated with benzodiazepine prescription at discharge from psychiatric inpatient treatment. Gen Hosp Psychiatry. 2015;37(6):595-600. https:\/\/doi.org\/10.1016\/j.genhosppsych.2015.06.004","journal-title":"Gen Hosp Psychiatry."},{"key":"9499_CR196","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.genhosppsych.2023.09.002","volume":"85","author":"S Dore","year":"2023","unstructured":"Dore S, Weleff J, Anand A, Thompson NR, Barnett BS. Race, economic status, and disparities in the receipt of benzodiazepine prescriptions in a large primary care sample. Gen Hosp Psychiatry. 2023;85:28-34. https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.09.002","journal-title":"Gen Hosp Psychiatry."},{"issue":"1","key":"9499_CR197","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s40615-021-01224-z","volume":"10","author":"J Ribas Roca","year":"2023","unstructured":"Ribas Roca J, Everett T, Dongarwar D, Salihu HM. Racial-Ethnic Disparities in Benzodiazepine Prescriptions for Anxiety in US Emergency Departments. J Racial Ethn Health Disparities. 2023;10(1):334-342. https:\/\/doi.org\/10.1007\/s40615-021-01224-z","journal-title":"J Racial Ethn Health Disparities."},{"issue":"5","key":"9499_CR198","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archinte.166.5.572","volume":"166","author":"SA Pearson","year":"2006","unstructured":"Pearson SA, Soumerai S, Mah C, et al. Racial disparities in access after regulatory surveillance of benzodiazepines. Arch Intern Med. 2006;166(5):572-579. https:\/\/doi.org\/10.1001\/archinte.166.5.572","journal-title":"Arch Intern Med."},{"issue":"1","key":"9499_CR199","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/08897077.2015.1129388","volume":"37","author":"M Komaromy","year":"2016","unstructured":"Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): A New Model for Educating Primary Care Providers about Treatment of Substance Use Disorders. Subst Abus. 2016;37(1):20-24. https:\/\/doi.org\/10.1080\/08897077.2015.1129388","journal-title":"Subst Abus."},{"key":"9499_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125320967183","volume":"10","author":"A Guy","year":"2020","unstructured":"Guy A, Brown M, Lewis S, Horowitz M. The \u2018patient voice\u2019: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Ther Adv Psychopharmacol. 2020;10:1-15. https:\/\/doi.org\/10.1177\/2045125320967183","journal-title":"Ther Adv Psychopharmacol."},{"issue":"5","key":"9499_CR201","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003983","volume":"19","author":"C Vicens","year":"2022","unstructured":"Vicens C, Leiva A, Bejarano F, et al. Evaluation of a multicomponent intervention consisting of education and feedback to reduce benzodiazepine prescriptions by general practitioners: The BENZORED hybrid type 1 cluster randomized controlled trial. PLoS Med. 2022;19(5):e1003983. https:\/\/doi.org\/10.1371\/journal.pmed.1003983","journal-title":"PLoS Med."},{"issue":"4","key":"9499_CR202","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/JHQ.0000000000000097","volume":"40","author":"C Hoffmann","year":"2018","unstructured":"Hoffmann C, Schweighardt A, Conn KM, et al. Enhanced Adherence in Patients Using an Automated Home Medication Dispenser. J Healthc Qual. 2018;40(4):194-200. https:\/\/doi.org\/10.1097\/JHQ.0000000000000097","journal-title":"J Healthc Qual."},{"issue":"1","key":"9499_CR203","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13722-018-0122-4","volume":"13","author":"Z Schuman-Olivier","year":"2018","unstructured":"Schuman-Olivier Z, Borodovsky JT, Steinkamp J, et al. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine\/naloxone adherence during opioid use disorder treatment: a pilot study. Addict Sci Clin Pract. 2018;13(1):21. https:\/\/doi.org\/10.1186\/s13722-018-0122-4","journal-title":"Addict Sci Clin Pract."},{"issue":"6","key":"9499_CR204","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1007\/s11325-023-02851-y","volume":"27","author":"T Hathorn","year":"2023","unstructured":"Hathorn T, Byun YJ, Rosen R, Sharma A. Clinical utility of smartphone applications for sleep physicians. Sleep Breath. 2023;27(6):2371-2377.","journal-title":"Sleep Breath."},{"issue":"3","key":"9499_CR205","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jsmc.2023.05.008","volume":"18","author":"TJ Doty","year":"2023","unstructured":"Doty TJ, Stekl EK, Bohn M, Klosterman G, Simonelli G, Collen J. A 2022 Survey of Commercially Available Smartphone Apps for Sleep: Most Enhance Sleep. Sleep Med Clin. 2023;18(3):373-384. https:\/\/doi.org\/10.1016\/j.jsmc.2023.05.008","journal-title":"Sleep Med Clin."},{"issue":"9","key":"9499_CR206","doi-asserted-by":"publisher","DOI":"10.2196\/39454","volume":"9","author":"SC Lu","year":"2022","unstructured":"Lu SC, Xu M, Wang M, et al. Effectiveness and Minimum Effective Dose of App-Based Mobile Health Interventions for Anxiety and Depression Symptom Reduction: Systematic Review and Meta-Analysis. JMIR Ment Health. 2022;9(9):e39454. https:\/\/doi.org\/10.2196\/39454","journal-title":"JMIR Ment Health."},{"issue":"8","key":"9499_CR207","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.7740","volume":"19","author":"AL Rathbone","year":"2017","unstructured":"Rathbone AL, Prescott J. The Use of Mobile Apps and SMS Messaging as Physical and Mental Health Interventions: Systematic Review. J Med Internet Res. 2017;19(8):e295. https:\/\/doi.org\/10.2196\/jmir.7740","journal-title":"J Med Internet Res."},{"issue":"1","key":"9499_CR208","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13030-021-00219-w","volume":"15","author":"M Nakao","year":"2021","unstructured":"Nakao M, Shirotsuki K, Sugaya N. Cognitive-behavioral therapy for management of mental health and stress-related disorders: Recent advances in techniques and technologies. Biopsychosoc Med. 2021;15(1):16. https:\/\/doi.org\/10.1186\/s13030-021-00219-w","journal-title":"Biopsychosoc Med."},{"key":"9499_CR209","doi-asserted-by":"publisher","unstructured":"Procyshyn R, Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs. Hogrefe Verlag GmbH & Co. KG; 2021. https:\/\/elibrary.hogrefe.com\/book\/https:\/\/doi.org\/10.1027\/00593-000","DOI":"10.1027\/00593-000"},{"key":"9499_CR210","unstructured":"Aronson JK ed. Meyler\u2019s Side Effects of Drugs. The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th ed. Elsevier; 2016."},{"key":"9499_CR211","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1600-0447.1986.tb08975.x","volume":"332","author":"L Dettli","year":"1986","unstructured":"Dettli L. Benzodiazepines in the treatment of sleep disorders: pharmacokinetic aspects. Acta Psychiatr Scand Suppl. 1986;332:9-19. https:\/\/doi.org\/10.1111\/j.1600-0447.1986.tb08975.x","journal-title":"Acta Psychiatr Scand Suppl."},{"key":"9499_CR212","unstructured":"Department of Veterans Affiars, Department of Defense. VA\/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. 2021."},{"key":"9499_CR213","volume-title":"Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual)","author":"CH Ashton","year":"2002","unstructured":"Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002."},{"key":"9499_CR214","unstructured":"Ashton, H. Benzodiazepine Equivalence Table [Online]. Revised April 2007. https:\/\/www.benzo.org.uk\/bzequiv.htm"},{"issue":"3","key":"9499_CR215","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","volume":"18","author":"CH Ashton","year":"2005","unstructured":"Ashton CH. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249-255. https:\/\/doi.org\/10.1097\/01.yco.0000165594.60434.84","journal-title":"Curr Opin Psychiatry."},{"issue":"8","key":"9499_CR216","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.brat.2010.04.002","volume":"48","author":"MW Otto","year":"2010","unstructured":"Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther. 2010;48(8):720-727. https:\/\/doi.org\/10.1016\/j.brat.2010.04.002","journal-title":"Behav Res Ther."},{"issue":"10","key":"9499_CR217","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1176\/ajp.150.10.1485","volume":"150","author":"MW Otto","year":"1993","unstructured":"Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy. Am J Psychiatry. 1993;150(10):1485-1490.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"9499_CR218","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/ajp.151.6.876","volume":"151","author":"DA Spiegel","year":"1994","unstructured":"Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry. 1994;151(6):876-881.","journal-title":"Am J Psychiatry."},{"issue":"1","key":"9499_CR219","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cpp.556","volume":"15","author":"K O\u2019Connor","year":"2008","unstructured":"O\u2019Connor K, Marchand A, Brousseau L, et al. Cognitive-behavioural, pharmacological and psychosocial predictors of outcome during tapered discontinuation of benzodiazepine. Clin Psychol Psychother. 2008;15(1):1-14. https:\/\/doi.org\/10.1002\/cpp.556","journal-title":"Clin Psychol Psychother."},{"key":"9499_CR220","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1192\/bjp.182.6.498","volume":"182","author":"RC Oude Voshaar","year":"2003","unstructured":"Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry. 2003;182:498-504. https:\/\/doi.org\/10.1192\/bjp.182.6.498","journal-title":"Br J Psychiatry."},{"issue":"5","key":"9499_CR221","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1037\/0022-006X.74.5.908","volume":"74","author":"P Gosselin","year":"2006","unstructured":"Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74(5):908-919. https:\/\/doi.org\/10.1037\/0022-006X.74.5.908","journal-title":"J Consult Clin Psychol."},{"issue":"3","key":"9499_CR222","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jbct.2023.09.003","volume":"33","author":"B Klein","year":"2023","unstructured":"Klein B, Oldenhof E, Nguyen H, Schattner P, Shandley K. Exploration of the preliminary effectiveness and acceptability of a self-help digital intervention to support benzodiazepine cessation and improve mental health and wellbeing: A one-group pilot trial. J Behav Cogn Ther. 2023;33(3):179-193. https:\/\/doi.org\/10.1016\/j.jbct.2023.09.003","journal-title":"J Behav Cogn Ther."},{"issue":"4","key":"9499_CR223","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/sleep\/zsac278","volume":"46","author":"K Coteur","year":"2023","unstructured":"Coteur K, Henrard G, Schoenmakers B, et al. Blended care to discontinue benzodiazepine receptor agonists use in patients with chronic insomnia disorder: a pragmatic cluster randomized controlled trial in primary care. Sleep. 2023;46(4):zsac278. https:\/\/doi.org\/10.1093\/sleep\/zsac278","journal-title":"Sleep."},{"issue":"2","key":"9499_CR224","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1176\/appi.ajp.161.2.332","volume":"161","author":"CM Morin","year":"2004","unstructured":"Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Valli\u00e8res A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry. 2004;161(2):332-342. https:\/\/doi.org\/10.1176\/appi.ajp.161.2.332","journal-title":"Am J Psychiatry."},{"issue":"10","key":"9499_CR225","first-page":"1015","volume":"169","author":"L Baillargeon","year":"2003","unstructured":"Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Gr\u00e9goire JP, Morin CM. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ. 2003;169(10):1015-1020.","journal-title":"CMAJ."},{"issue":"5","key":"9499_CR226","first-page":"339","volume":"64","author":"K Pottie","year":"2018","unstructured":"Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.","journal-title":"Can Fam Physician."},{"issue":"6","key":"9499_CR227","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/bcp.12294","volume":"77","author":"R L\u00e4hteenm\u00e4ki","year":"2014","unstructured":"L\u00e4hteenm\u00e4ki R, Puustinen J, Vahlberg T, et al. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77(6):975-985. https:\/\/doi.org\/10.1111\/bcp.12294","journal-title":"Br J Clin Pharmacol."},{"key":"9499_CR228","unstructured":"Reconnexion. The Benzodiazepine Toolkit. Toolkit. 2018."},{"key":"9499_CR229","volume-title":"Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual)","author":"CH Ashton","year":"2002","unstructured":"Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002."},{"issue":"3","key":"9499_CR230","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12529-021-10002-4","volume":"29","author":"VV Barros","year":"2022","unstructured":"Barros VV, Opaleye ES, Demarzo M, et al. Effects of mindfulness-based relapse prevention on the chronic use of hypnotics in treatment-seeking women with insomnia: a randomized controlled trial. Int J Behav Med. 2022;29(3):266-277. https:\/\/doi.org\/10.1007\/s12529-021-10002-4","journal-title":"Int J Behav Med."},{"key":"9499_CR231","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2018.11.015","volume":"109","author":"WF Yeung","year":"2019","unstructured":"Yeung WF, Chung KF, Zhang ZJ, et al. Electroacupuncture for tapering off long-term benzodiazepine use: a randomized controlled trial. Article. J Psychiatr Res. 2019;109:59-67. https:\/\/doi.org\/10.1016\/j.jpsychires.2018.11.015","journal-title":"Article. J Psychiatr Res."},{"issue":"2","key":"9499_CR232","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0005-7967(95)00051-8","volume":"34","author":"K Elsesser","year":"1996","unstructured":"Elsesser K, Sartory G, Maurer J. The efficacy of complaints management training in facilitating benzodiazepine withdrawal. Behav Res Ther. 1996;34(2):149-156. https:\/\/doi.org\/10.1016\/0005-7967(95)00051-8","journal-title":"Behav Res Ther."},{"key":"9499_CR233","unstructured":"National Institutes for Health and Care Excellence. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. 2022."},{"issue":"4","key":"9499_CR234","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/hex.13547","volume":"25","author":"T Lynch","year":"2022","unstructured":"Lynch T, Ryan C, Bradley C, et al. Supporting safe and gradual reduction of long-term benzodiazepine receptor agonist use: development of the SAFEGUARDING-BZRAs toolkit using a codesign approach. Health Expect. 2022;25(4):1904-1918. https:\/\/doi.org\/10.1111\/hex.13547","journal-title":"Health Expect."},{"issue":"5","key":"9499_CR235","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5664\/jcsm.27286","volume":"4","author":"S Schutte-Rodin","year":"2008","unstructured":"Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.","journal-title":"Journal of clinical sleep medicine."},{"issue":"2","key":"9499_CR236","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. Feb 15 2017;13(2):307-349. https:\/\/doi.org\/10.5664\/jcsm.6470","journal-title":"J Clin Sleep Med."},{"issue":"5","key":"9499_CR237","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/bfm.2020.0259","volume":"16","author":"A Nishimura","year":"2021","unstructured":"Nishimura A, Furugen A, Umazume T, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. Breastfeed Med. 2021;16(5):424-431. https:\/\/doi.org\/10.1089\/bfm.2020.0259","journal-title":"Breastfeed Med."},{"issue":"6","key":"9499_CR238","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0890-6238(94)90029-9","volume":"8","author":"PR McElhatton","year":"1994","unstructured":"McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994;8(6):461-475. https:\/\/doi.org\/10.1016\/0890-6238(94)90029-9","journal-title":"Reprod Toxicol."},{"issue":"2","key":"9499_CR239","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF00544570","volume":"33","author":"M Wretlind","year":"1987","unstructured":"Wretlind M. Excretion of oxazepam in breast milk. Eur J Clin Pharmacol. 1987;33(2):209-210. https:\/\/doi.org\/10.1007\/BF00544570","journal-title":"Eur J Clin Pharmacol."},{"issue":"10","key":"9499_CR240","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/j.1552-4604.1984.tb01819.x","volume":"24","author":"JM Hilbert","year":"1984","unstructured":"Hilbert JM, Gural RO, Symchowicz S, Zampaglione N. Excretion of Quazepam Into Human Breast Milk. J Clin Pharmacol. 1984;24(10):457-462. https:\/\/doi.org\/10.1002\/j.1552-4604.1984.tb01819.x","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"9499_CR241","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1365-2125.1992.tb04029.x","volume":"33","author":"TH Lebedevs","year":"1992","unstructured":"Lebedevs TH, Wojnar-Horton RE, Yapp P, et al. Excretion of temazepam in breast milk. Br J Clin Pharmacol. 1992;33(2):204-206. https:\/\/doi.org\/10.1111\/j.1365-2125.1992.tb04029.x","journal-title":"Br J Clin Pharmacol."},{"issue":"11","key":"9499_CR242","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/pds.1457","volume":"16","author":"BN Wikner","year":"2007","unstructured":"Wikner BN, Stiller C-O, Bergman U, Asker C, K\u00e4ll\u00e9n B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(11):1203-1210. https:\/\/doi.org\/10.1002\/pds.1457","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"9499_CR243","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.psym.2018.03.009","volume":"59","author":"SK Chaudhry","year":"2018","unstructured":"Chaudhry SK, Susser LC. Considerations in treating insomnia during pregnancy: a literature review. Psychosomatics. 2018;59(4):341-348. https:\/\/doi.org\/10.1016\/j.psym.2018.03.009","journal-title":"Psychosomatics."},{"issue":"3","key":"9499_CR244","doi-asserted-by":"publisher","first-page":"151221","DOI":"10.1016\/j.semperi.2020.151221","volume":"44","author":"EA Pinheiro","year":"2020","unstructured":"Pinheiro EA, Stika CS. Drugs in pregnancy: pharmacologic and physiologic changes that affect clinical care. Semin Perinatol. 2020;44(3):151221. https:\/\/doi.org\/10.1016\/j.semperi.2020.151221","journal-title":"Semin Perinatol."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09499-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:02:49Z","timestamp":1758816169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09499-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":244,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9499"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09499-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"The authors declare that they do not have a conflict of interest. All authors completed Disclosure of Interest forms, which can be found in Supplementary Material\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}}]}}